

# Sequestrins – New small protein drugs targeting neurodegenerative disorders

<https://www.neurodegenerationresearch.eu/survey/sequestrins-new-small-protein-drugs-targeting-neurodegenerative-disorders/>

## Principal Investigators

Stefan Ståhl

## Institution

KTH Royal Institute of Technology

## Contact information of lead PI

### Country

Sweden

## Title of project or programme

Sequestrins - New small protein drugs targeting neurodegenerative disorders

## Source of funding information

The Swedish Brain Foundation

## Total sum awarded (Euro)

€ 108,814

## Start date of award

01/07/2015

## Total duration of award in years

2.5

## Keywords

### Research Abstract

This application is motivated by very positive and encouraging recent preclinical results (described below) from a novel therapeutic approach in the field of Alzheimer's disease (AD). The overall objective is to explore how small affinity proteins can be utilized as new types of protein drugs for neurodegenerative disorders. Affinity proteins have indeed proven suitable for targeting applications, e.g. to detect cancer tumors, but also as capturing agents for blocking of protein:protein interactions and even to sequester proteins in the circulation. This proposal intends to explore a novel and challenging biotherapy strategy. Very small affinity proteins,

termed sequestrins, that are developed in-house, will be investigated as in vivo capturing agents aimed towards future treatment of neurodegenerative disorders, with an initial focus on AD. A sequestrin is a new type of protein scaffold, based on head-to-tail-linked affibody molecules, aimed to act as “molecular tweezers” capturing aggregation-prone peptides and proteins.

**Further information available at:**

**Types:**

Investments < €500k

**Member States:**

Sweden

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A